On-demand blood will enable military medical professionals to access to quality blood supplies from anywhere in the world. The Geneva Foundation (Geneva) announces today the expansion of the 4-Defense Biotechnology, Biomanufacturing and Bioprinting Center (4D Bio3) program, a federally-funded partnership based at the Uniformed Services University (USU) and administered by Geneva, with the addition of 4,037
HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO
A team of clinical and technical experts will provide urgently needed comprehensive solutions for clinical, informational, technical, training, and deployment aspects in order to bring critical care resources to every bedside. The Geneva Foundation (Geneva) and the Telemedical Research for Operational Support (TR4OS) program of Madigan Army Medical Center has been selected to create
The 3D Biofabrication Facility was launched in mid-2019 and marks the first-ever 3D printer capable of manufacturing human tissue (including, someday, organs) in microgravity. The Geneva Foundation (Geneva), in partnership with the Uniformed Services University of the Health Sciences (USU), commercial space company TechShot, Inc, and 3D printer manufacturer nScrypt, Inc., have successfully completed
The Geneva Foundation (Geneva), in partnership with the Broussard Foundation, brought together more than 50 military leaders, clinicians, scientists, and experts within the physical therapy, orthopedics, physical medicine, and pain management fields for the first ever Tri-Service Post-Operative Rehabilitation Protocol Consensus Meeting to standardize disparate protocols for military healthcare. The Musculoskeletal Injury Rehabilitation Research for
Army scientists working with partners from industry and academia have developed an experimental treatment that protects animals from Sudan virus, which is closely related to Ebola. Their work is published online today in the journal Proceedings of the National Academy of Sciences. There are six distinct species of ebolaviruses, which collectively pose a significant threat
The Geneva Foundation and the Uniformed Services University (USU) 4D Bio3 Program, in support of the U.S. Military, recently completed a pilot project involving the biofabrication of medical products in an austere military environment, with the goal of advancing future nextgeneration treatments for the Nation’s deployed warfighters. Advances in 3D printing and biofabrication have the
Orlando, FL-based nScrypt has partnered with the U.S. Military, the Uniformed Services University 4D Bio3 Program, RoosterBio, Inc, and The Geneva Foundation to move bioprinting out of sterile biology laboratories to forward-deployed military positions. For this project, nScrypt has customized its BioAssembly Tool (BAT) bioprinter, which won the 2003 R&D 100 award and is scheduled
CIRCULOGENE molecular diagnostics laboratory, a subcontractor to The Geneva Foundation (Geneva), which has been awarded a $1.5 million U.S. Department of Defense grant, is to develop liquid biopsy markers for the rapid and accurate assessment of traumatic brain injury (TBI). The Defense Medical Research and Development Program (DMRDP) Precision Trauma Care Research Award (PTCRA) is
The Geneva Foundation (Geneva) is honored to announce the 2018 Researcher of the Year award recipient. Senior Nurse Scientist MAJ (Ret.) Mary McCarthy, PhD was selected as Geneva’s 2018 Researcher of the Year in recognition of her longstanding commitment to and excellence in military nursing research, with notable contributions in research quality and research mentorship.